NPC Updates
- June, 2002
This Issue:
- A Focus on Incremental Pharmaceutical Innovation
NPC IS PLEASED TO OFFER THE FOLLOWING RESOURCES RELATING TO THE CURRENT
DISCUSSIONS ON THE VALUE OF INCREMENTAL PHARMACEUTICAL INNOVATIONS
- Assessing
the Impact of Pharmaceutical Innovation: A Comprehensive Framework,
by Jack A. Meyer, Ph.D., 2002
This report shows that new drugs are yielding a wide range of benefits
to our society that more than justify the investment needed to produce
them. This report develops a comprehensive framework for assessing the
value of pharmaceutical innovation that encompasses both the cost of
bringing new products to market and the direct and indirect benefits.
(For more information view our Fact
sheet.
- Executive
Summary: Too Many Drugs? The Clinical and Economic Value of Incremental
Innovations, by Albert Wertheimer, Ph.D., MBA, et al., 2002
This summary addresses the need for a fully developed class of drugs
in order to allow precision prescribing for the best health outcomes,
as presented in the full report described below.
- Too
Many Drugs? The Clinical and Economic Value of Incremental Innovations,
by Albert Wertheimer, Ph.D., MBA, et al., reprinted from "Research
In Human Capital And Development, Investing in Health: The Social and
Economic Benefits of Health Care Innovation," Vol. 14, 2001
The history of clinical pharmacology is characterized by incremental
improvements in the safety, efficacy, selectivity, and utility of drugs
within a given class. This report makes the case for a fully developed
class of drugs to allow precision prescribing in order to achieve optimum
outcomes in the most cost effective manner.
- The
Value of Incremental Pharmaceutical Innovation for Older Americans,
by Albert Wertheimer, Ph.D., MBA, et al., 2001
This monograph explains that small incremental improvements within drug
classes provide important health benefits, especially for elderly patients.
The monograph illustrates that therapeutic advantages of these newer
drugs in a class include: fewer side effects, improved safety and greater
effectiveness; easier use, which facilitates compliance with prescribed
regimens; and better tailoring to fit individual patient needs.
- Fact sheets available at the following links:
- Measuring the Value of Health Innovation: The Policy Implications
of New Medical Technologies, A Briefing on the Benefits and Costs of
Medical Progress, September 7, 2001. Featured articles, research summaries
and video highlights from the symposium are available on the CD-ROM
"The Value of Medical Innovation."
- The September/October 2001 issue of the journal "Health Affairs"
featured a new body of peer-reviewed research discussing the value of
innovation. Taken together, this research is seminal in the national
conversation on the issue of drug costs and spending. The Alliance for
Health Reform, in cooperation with NPC and the Merck Foundation, sponsored
a symposium and panel discussion on September 7, 2001, which focused
on this new research. A transcript of the symposium is available here.
To order any of these publications in hard copy (free of charge), please
go to our order form or call
(703) 620-6390.
Since 1953, NPC has sponsored and conducted scientific, evidence-based
analyses of the appropriate use of pharmaceuticals and the clinical and
economic value of pharmaceutical innovation. NPC provides educational
resources to a variety of health care stakeholders, including patients,
clinicians, payers and policy makers. More than 20 research-based pharmaceutical
companies are members of the NPC.
We encourage you to pass this message on to colleagues who may find this
information useful. To subscribe please click
here. To unsubscribe, please send an email to
main@npcnow.com with the word "unsubscribe" in the subject
line. |
